Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery
Open Access
- 29 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-16
- https://doi.org/10.1038/s41467-020-18548-9
Abstract
The CRISPR-Cas9 system has increased the speed and precision of genetic editing in cells and animals. However, model generation for drug development is still expensive and time-consuming, demanding more target flexibility and faster turnaround times with high reproducibility. The generation of a tightly controlled ObLiGaRe doxycycline inducible SpCas9 (ODInCas9) transgene and its use in targeted ObLiGaRe results in functional integration into both human and mouse cells culminating in the generation of the ODInCas9 mouse. Genomic editing can be performed in cells of various tissue origins without any detectable gene editing in the absence of doxycycline. Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enabling treatment studies to validate the efficacy of candidate drugs. The ODInCas9 mouse allows robust and tunable genome editing granting flexibility, speed and uniformity at less cost, leading to high throughput and practical preclinical in vivo therapeutic testing.Funding Information
- AstraZeneca
This publication has 53 references indexed in Scilit:
- One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome EngineeringCell, 2013
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature, 2012
- Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinomaProceedings of the National Academy of Sciences of the United States of America, 2012
- Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse modelsBioEssays, 2011
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- Suppression of lung adenocarcinoma progression by Nkx2-1Nature, 2011
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- LKB1 modulates lung cancer differentiation and metastasisNature, 2007
- Ubiquitous and uniform in vivo fluorescence in ROSA26-EGFP BAC transgenic micegenesis, 2007
- Cryptic loxP sites in mammalian genomes: genome-wide distribution and relevance for the efficiency of BAC/PAC recombineering techniquesNucleic Acids Research, 2007